Literature DB >> 32800407

Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study.

Fredrik Liedberg1, Petter Kollberg2, Marie Allerbo3, Gediminas Baseckas4, Johan Brändstedt4, Sigurdur Gudjonsson5, Oskar Hagberg6, Ulf Håkansson7, Tomas Jerlström8, Annica Löfgren9, Oliver Patschan4, Anne Sörenby4, Mats Bläckberg3.   

Abstract

BACKGROUND: Parastomal hernia (PSH) after urinary diversion with ileal conduit is frequently a clinical problem.
OBJECTIVE: To investigate whether a prophylactic lightweight mesh in the sublay position can reduce the cumulative incidence of PSH after open cystectomy with ileal conduit. DESIGN, SETTING, AND PARTICIPANTS: From 2012 to 2017, we randomised 242 patients 1:1 to conventional stoma construction (n = 124) or prophylactic mesh (n = 118) at three Swedish hospitals (ISRCTN 95093825). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was clinical PSH, and secondary endpoints were radiological PSH assessed in prone position with the stoma in the centre of a ring, parastomal bulging, and complications from the mesh. RESULTS AND LIMITATIONS: Within 24 mo, 20/89 (23%) patients in the control arm and 10/92 (11%) in the intervention arm had developed a clinical PSH (p = 0.06) after a median follow-up of 3 yr, corresponding to a hazard ratio of 0.45 (confidence interval 0.24-0.86, p = 0.02) in the intervention arm. The proportions of radiological PSHs within 24 mo were 22/89 (25%) and 17/92 (19%) in the two study arms. During follow-up, five patients in the control arm and two in the intervention arm were operated for PSH. The median operating time was 50 min longer in patients receiving a mesh. No differences were noted in proportions of Clavien-Dindo complications at 90 d postoperatively or in complications related to the mesh during follow-up.
CONCLUSIONS: Prophylactic implantation of a lightweight mesh in the sublay position decreases the risk of PSH when constructing an ileal conduit without increasing the risk of complications related to the mesh. The median surgical time is prolonged by mesh implantation. PATIENT
SUMMARY: In this randomised report, we looked at the risk of parastomal hernia after cystectomy and urinary diversion with ileal conduit with or without the use of a prophylactic mesh. We conclude that such a prophylactic measure decreased the occurrence of parastomal hernias, with only a slight increase in operating time and no added risk of complications related to the mesh.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Cystectomy; Ileal conduit; Parastomal hernia; Prophylactic mesh

Mesh:

Year:  2020        PMID: 32800407     DOI: 10.1016/j.eururo.2020.07.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

1.  Cost Effectiveness of the Use of Prophylactic Mesh To Prevent Parastomal Hernia After Urinary Diversion with an Ileal Conduit.

Authors:  Sanjib Saha; Ulf Gerdtham; Mats Bläckberg; Petter Kollberg; Fredrik Liedberg
Journal:  Eur Urol Open Sci       Date:  2022-04-21

2.  Keyhole versus Sugarbaker techniques in parastomal hernia repair following ileal conduit urinary diversion: a retrospective nationwide cohort study.

Authors:  Elisa Mäkäräinen-Uhlbäck; Jaana Vironen; Markku Vaarala; Pia Nordström; Anu Välikoski; Jyrki Kössi; Ville Falenius; Aristotelis Kechagias; Anne Mattila; Pasi Ohtonen; Tom Scheinin; Tero Rautio
Journal:  BMC Surg       Date:  2021-05-03       Impact factor: 2.102

3.  Parastomal hernias after cystectomy and ileal conduit urinary diversion: surgical treatment and the use of prophylactic mesh: a systematic review.

Authors:  M Dewulf; N D Hildebrand; S A W Bouwense; N D Bouvy; F Muysoms
Journal:  BMC Surg       Date:  2022-03-29       Impact factor: 2.102

4.  Incidence and risk factors of parastomal hernia after radical cystectomy and ileal conduit diversion: a systematic review and meta-analysis.

Authors:  Dechao Feng; Zhenghao Wang; Yubo Yang; Dengxiong Li; Wuran Wei; Li Li
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.